Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Efficacy and safety of a Belgian tertiary care outpatient parenteral antimicrobial therapy (OPAT) program

  • 8 Accesses



Evidence supports the implementation of outpatient parenteral antimicrobial therapy (OPAT) as standard of care. Until 2015 the overall experience with OPAT in Belgium remained limited. The aim of this study was to evaluate the efficacy and safety of a Belgian ‘OPAT at home’ program, which was implemented in University Hospitals Leuven starting from January 2017.


A mono-centric, prospective, observational study was carried out. All OPAT cases discharged between 10 January 2017 and 10 January 2019 were included in the study. Relevant demographic and clinical patient data were collected. The outcomes were clinical cure rate, OPAT related readmission rate, adverse event rate and patients’ satisfaction.


Over the two-year study period, 152 OPAT episodes were started in 130 patients, resulting in 3153 avoided hospitalization days which corresponds to 5.4 freed hospital beds. Urinary tract infections accounted for 40.8% of OPAT courses and temocillin was the most frequently used antibiotic (24.3%). Cure was achieved in 97.9% of the OPAT episodes. During 22 (14.5%) OPAT episodes, patients experienced adverse events, including line related adverse events (7.9%) and adverse drug events (6.6%). An OPAT related readmission rate of 9.2% was observed, mostly related to line-associated adverse events. All patients who completed the satisfaction survey (n = 23) were very satisfied with their OPAT course.


The University Hospitals Leuven OPAT program is associated with a high level of clinical cure and low all-cause readmission and adverse event rates. Improvement actions are described to further reduce the readmission rate to less than 5.0%.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4


  1. 1.

    Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis. 2004;38:1651–72. https://doi.org/10.1086/420939.

  2. 2.

    Rucker RW, Harrison GM. Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics. 1974;54:358–60.

  3. 3.

    Norris AH, Shrestha NK, Allison GM, Keller SC, Bhavan KP, Zurlo JJ et al. 2018 IDSA Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapya. Clin Infect Dis. 2018:ciy745-ciy. https://doi.org/10.1093/cid/ciy745.

  4. 4.

    Chapman ALN, Patel S, Horner C, Gilchrist M, Seaton RA. Outpatient parenteral antimicrobial therapy: updated recommendations from the UK. J Antimicrob Chemother. 2019;74:3125–7. https://doi.org/10.1093/jac/dkz343.

  5. 5.

    Chapman AL, Seaton RA, Cooper MA, Hedderwick S, Goodall V, Reed C, et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother. 2012;67:1053–62. https://doi.org/10.1093/jac/dks003.

  6. 6.

    Minton J, Murray CC, Meads D, Hess S, Vargas-Palacios A, Mitchell E et al. The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy Health Services and Delivery Research. 2017;5:1. https://doi.org/10.3310/hsdr05060.

  7. 7.

    Erba A, Beuret M, Daly ML, Khanna N, Osthoff M. OPAT in Switzerland: single-center experience of a model to treat complicated infections. Infection. 2019. https://doi.org/10.1007/s15010-019-01381-8.

  8. 8.

    Rigor J, Ferreira PM, Murteira F, Figueiredo C, Vieira N, Oliveira R, et al. Antibiotic clinic: two years' experience in outpatient parenteral antimicrobial therapy in a Portuguese hospital. Acta Med Port. 2019;32:576–9. https://doi.org/10.20344/amp.11730.

  9. 9.

    Wijnakker R, Visser LE, Schippers EF, Visser LG, van Burgel ND, van Nieuwkoop C. The impact of an infectious disease expert team on outpatient parenteral antimicrobial treatment in the Netherlands. Int J Clin Pharm. 2019;41:49–55. https://doi.org/10.1007/s11096-018-0751-4.

  10. 10.

    Nathwani D, Conlon C. Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party. Clin Microbiol Infect. 1998;4:537–51. https://doi.org/10.1111/j.1469-0691.1998.tb00413.x.

  11. 11.

    Gardiol C, Voumard R, Cochet C, de Valliere S. Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity. Eur J Clin Microbiol Infect Dis. 2016;35:839–45. https://doi.org/10.1007/s10096-016-2606-z.

  12. 12.

    MacKenzie M, Rae N, Nathwani D. Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: a review of the last decade. Int J Antimicrob Agents. 2014;43:7–16. https://doi.org/10.1016/j.ijantimicag.2013.09.006.

  13. 13.

    Ponce Gonzalez MA, Miron Rubio M, Mujal Martinez A, Estrada Cuxart O, Fiuza Perez D, Salas Reinoso L, et al. Effectiveness and safety of outpatient parenteral antimicrobial therapy in acute exacerbation of chronic obstructive pulmonary disease. Int J Clin Pract. 2017. https://doi.org/10.1111/ijcp.13022.

  14. 14.

    Durojaiye OC, Bell H, Andrews D, Ntziora F, Cartwright K. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. Int J Antimicrob Agents. 2017. https://doi.org/10.1016/j.ijantimicag.2017.03.016.

  15. 15.

    Beguin Y, Benoit Y, Crokaert F, Selleslag D, Vandercam B. Outpatient and home parenteral antibiotic therapy (OHPAT) in low-risk febrile neutropenia: consensus statement of a Belgian panel. Acta Clin Belg. 2002;57:309–16. https://doi.org/10.1179/acb.2002.058.

  16. 16.

    Smismans A, Vantrappen A, Verbiest F, Indevuyst C, Van den Poel B, von Winckelmann S, et al. OPAT: proof of concept in a peripheral Belgian hospital after review of the literature. Acta Clin Belg. 2018;1:1–11. https://doi.org/10.1080/17843286.2018.1424503.

  17. 17.

    Buyle FM, Ravelingien T, Vantrappen A, Deryckere S, von Winckelmann S, Sermijn E et al., editors. Outpatient parenteral antimicrobial therapy (OPAT) in Belgium: a national survey. ECCMID; 2016 2016//09/04. Amsterdam.

  18. 18.

    Ravelingien T, Buyle F, Deryckere S, Sermijn E, Debrauwere M, Verplancke K, et al. Optimization of a model of out-of-hospital antibiotic therapy (OPAT) in a Belgian university hospital resulting in a proposal for national implementation. Acta Clin Belg. 2016;19:1–6. https://doi.org/10.1080/17843286.2016.1183285.

  19. 19.

    Nathwani D, Zambrowski JJ, Ad HOCW. Advisory group on Home-based and Outpatient Care (AdHOC): an international consensus statement on non-inpatient parenteral therapy. Clin Microbiol Infect. 2000;6:464–76.

  20. 20.

    Eaves K, Thornton J, Chapman ALN. Patient retention of training in self-administration of intravenous antibiotic therapy in an outpatient parenteral antibiotic therapy service. J Clin Nurs. 2014;23:1318–22. https://doi.org/10.1111/jocn.12376.

  21. 21.

    De Block M. Plan van aanpak hervorming ziekenhuisfinanciering. Brussel: Beleidscel van de minister van Sociale Zaken en Volksgezondheid; 2015.

  22. 22.

    Goossens GA. Flushing and locking of venous catheters: available evidence and evidence deficit. Nurs Res Pract. 2015;2015:985686. https://doi.org/10.1155/2015/985686.

  23. 23.

    Nursing RCo. Standards for infusion therapy. 4 ed. London: Royal College of Nursing; 2016.

  24. 24.

    O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2011;39:S1–34. https://doi.org/10.1016/j.ajic.2011.01.003.

  25. 25.

    Mitchell ED, Czoski Murray C, Meads D, Minton J, Wright J, Twiddy M. Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review. BMJ Open. 2017;7:e013560. https://doi.org/10.1136/bmjopen-2016-013560.

  26. 26.

    McQuillen DP, MacIntyre AT. The value that infectious diseases physicians bring to the healthcare system. J Infect Dis. 2017;216:S588–S593593. https://doi.org/10.1093/infdis/jix326.

  27. 27.

    Dryden M, Saeed K, Townsend R, Winnard C, Bourne S, Parker N, et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother. 2012;67:2289–96. https://doi.org/10.1093/jac/dks193.

  28. 28.

    Heintz BH, Halilovic J, Christensen CL. Impact of a multidisciplinary team review of potential outpatient parenteral antimicrobial therapy prior to discharge from an academic medical center. Ann Pharmacother. 2011;45:1329–37. https://doi.org/10.1345/aph.1Q240.

  29. 29.

    Shrestha NK, Bhaskaran A, Scalera NM, Schmitt SK, Rehm SJ, Gordon SM. Contribution of infectious disease consultation toward the care of inpatients being considered for community-based parenteral anti-infective therapy. J Hosp Med. 2012;7:365–9. https://doi.org/10.1002/jhm.1902.

  30. 30.

    Means L, Bleasdale S, Sikka M, Gross AE. Predictors of hospital readmission in patients receiving outpatient parenteral antimicrobial therapy. Pharmacotherapy. 2016;36:934–9. https://doi.org/10.1002/phar.1799.

  31. 31.

    Huang V, Ruhe JJ, Lerner P, Fedorenko M. Risk factors for readmission in patients discharged with outpatient parenteral antimicrobial therapy: a retrospective cohort study. BMC Pharmacol Toxicol. 2018;19:50. https://doi.org/10.1186/s40360-018-0240-3.

  32. 32.

    Jacobs DM, Leung WY, Essi D, Park W, Shaver A, Claus J, et al. Incidence and risk factors for healthcare utilisation among patients discharged on outpatient parenteral antimicrobial therapy. Epidemiol Infect. 2018;146:782–7. https://doi.org/10.1017/S0950268818000456.

  33. 33.

    Durojaiye OC, Bell H, Andrews D, Ntziora F, Cartwright K. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. Int J Antimicrob Agents. 2018;51:26–322. https://doi.org/10.1016/j.ijantimicag.2017.03.016.

  34. 34.

    Foulon V, Wuyts J, Desplenter F, Spinewine A, Lacour V, Paulus D, et al. Problems in continuity of medication management upon transition between primary and secondary care: patients’ and professionals’ experiences. Acta Clin Belg. 2018;1:1–9. https://doi.org/10.1080/17843286.2018.1483561.

  35. 35.

    Gandhi TK, Lee TH. Patient safety beyond the Hospital. N Engl J Med. 2010;363:1001–3. https://doi.org/10.1056/NEJMp1003294.

  36. 36.

    Berland A, Bentsen SB. Medication errors in home care: a qualitative focus group study. J Clin Nurs. 2017;26:3734–41. https://doi.org/10.1111/jocn.13745.

  37. 37.

    Dreesen M, Foulon V, Vanhaecht K, De Pourcq L, Hiele M, Willems L. Identifying patient-centered quality indicators for the care of adult home parenteral nutrition (HPN) patients. JPEN. 2014;38:840–6. https://doi.org/10.1177/0148607113495891.

  38. 38.

    Twiddy M, Czoski Murray CJ, Mason SJ, Meads D, Wright JM, Mitchell ED, et al. A qualitative study of patients' feedback about Outpatient Parenteral Antimicrobial Therapy (OPAT) services in Northern England: implications for service improvement. BMJ Open. 2018;8:e019099. https://doi.org/10.1136/bmjopen-2017-019099.

  39. 39.

    Huck D, Ginsberg JP, Gordon SM, Nowacki AS, Rehm SJ, Shrestha NK. Association of laboratory test result availability and rehospitalizations in an outpatient parenteral antimicrobial therapy programme. J Antimicrob Chemother. 2014;69:228–33. https://doi.org/10.1093/jac/dkt303.

  40. 40.

    Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138:161–7. https://doi.org/10.7326/0003-4819-138-3-200302040-00007.

  41. 41.

    Holmboe ES, Lipner R, Greiner A. Assessing quality of care: Knowledge matters. JAMA. 2008;299:338–40. https://doi.org/10.1001/jama.299.3.338.

  42. 42.

    Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ (Clin Res Ed). 2014;348:g1687. https://doi.org/10.1136/bmj.g1687.

Download references


We acknowledge the contribution of the multidisciplinary OPAT team of University Hospitals Leuven.


This study was not funded.

Author information

Correspondence to Charlotte Quintens.

Ethics declarations

Conflict of interest

All authors declare that they have no competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Ethics Committee for Research, University Hospitals Leuven, Belgium; S60847) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Quintens, C., Steffens, E., Jacobs, K. et al. Efficacy and safety of a Belgian tertiary care outpatient parenteral antimicrobial therapy (OPAT) program. Infection (2020). https://doi.org/10.1007/s15010-020-01398-4

Download citation


  • Outpatient parenteral antimicrobial therapy
  • OPAT
  • Hospital at home
  • Home care
  • Antibiotics
  • Intravascular catheter care